pp-055 Injection
Dossier type
CTD
Dossier status
Under development
Country of origin
Japan
Comments
For wet age-related macular degeneration (wet AMD), targeting abnormal choroidal neovascularization and retinal damage.
Phase 2 clinical development.
Modality: Anti-FGF2 RNA aptamer (chemically modified oligonucleotide therapeutic).
Mechanism / Target: Selective inhibitor of fibroblast growth factor 2 (FGF2), a key driver of pathological angiogenesis, inflammation, and fibrosis in wet AMD. Aims to suppress VEGF-independent neovascular pathways that contribute to anti-VEGF resistance.
Route / form: Intravitreal injection.
Differentiation: Targets FGF2, a pathway not addressed by current anti-VEGF therapies. Potential to treat patients who respond poorly to anti-VEGF agents or who experience disease progression due to fibrosis.
Manufacturer #38604
A Japan-based biotech venture specializing in RNA aptamer drug discovery, with clinical-stage programs in ophthalmology and rare diseases. It leverages a proprietary aptamer-discovery platform and seeks global collaborations to bring next-generation nucleic-acid therapies to market.